Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults-Reference-Cited by-同舟云学术

Pharmacokinetics and phenotyping properties of the Basel phenotyping cocktail combination capsule in healthy male adults

Published:2019-12-12 Issue:2 Volume:86 Page:352-361
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Suenderhauf Claudia¹,Berger Benjamin¹²,Puchkov Maxim³,Schmid Yasmin¹,Müller Sabine¹⁴,Huwyler Jörg³,Haschke Manuel⁴⁵,Krähenbühl Stephan¹²,Duthaler Urs¹²^ORCID

Affiliation:

1. Division of Clinical Pharmacology & ToxicologyUniversity Hospital Basel Switzerland

2. Department of BiomedicineUniversity of Basel Switzerland

3. Department of Pharmaceutical SciencesUniversity of Basel Switzerland

4. Clinical Pharmacology and Toxicology, Department of General Internal Medicine, Inselspital, Bern University HospitalUniversity of Bern Switzerland

5. Institute of PharmacologyUniversity of Bern Switzerland

Funder

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14157

Reference29 articles.

1. Clinical importance of the cytochromes P450

2. Cytochrome P450 Pharmacogenetics in Drug Development: In Vitro Studies and Clinical Consequences

3. Extremely Rapid Hydroxylation of Debrisoquine

4. CYP2D6 genotyping and the pharmacogenetics of tamoxifen;Flockhart D;Clin Adv Hematol Oncol,2008

5. Complicated Pain Management in a CYP450 2D6 Poor Metabolizer

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of protein binding on the pharmacokinetics of the six substrates in the Basel phenotyping cocktail in healthy subjects and patients with liver cirrhosis;European Journal of Pharmaceutical Sciences;2024-11

2. Nutrimetric Validation of Solanidine as Dietary‐Derived CYP2D6 Activity Marker In Vivo;Clinical Pharmacology & Therapeutics;2023-12-03

3. Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects;Pharmacology Research & Perspectives;2023-10

4. Pharmacokinetic and Pharmacodynamic Drug–Drug Interactions: Research Methods and Applications;Metabolites;2023-07-29

5. The Activity of Members of the UDP-Glucuronosyltransferase Subfamilies UGT1A and UGT2B is Impaired in Patients with Liver Cirrhosis;Clinical Pharmacokinetics;2023-06-16